Skip to content
Review

Oral antihypertensive agents in pregnancy

Abstract

Hypertensive disorders of pregnancy (HDP) affect up to 10% of pregnancies worldwide and represent a primary cause of maternal and perinatal morbidity and mortality, giving rise to acute maternal complications such as HELLP syndrome and eclampsia, as well as fetal growth restriction (FGR) and preterm birth. To manage maternal blood pressure and safely prolong pregnancy, oral antihypertensive agents - most commonly methyldopa, labetalol, and nifedipine - are widely administered. However, international clinical guidelines provide inconsistent recommendations, and comparative evidence regarding neonatal safety and long-term outcomes remains limited. As a result, substantial variation in the management of HDP persists in clinical practice. Our network meta-analysis including randomized controlled trials comparing the three most commonly administered oral antihypertensive agents demonstrated no significant superiority among methyldopa, labetalol, or nifedipine with respect to severe hypertension or birth weight. Although labetalol showed a modest reduction in preeclampsia diagnoses and preterm births compared to nifedipine, this difference is likely attributable to nifedipine-induced renal afferent arteriole vasodilation, which increases proteinuria and accelerates preeclampsia diagnoses rather than reflecting true harm. Furthermore, tailoring antihypertensive selection to individual hemodynamic profiles currently lacks sufficient empirical support to demonstrate improved clinical outcomes. Crucially, across a large Dutch population-based cohort study including 11,145 pregnancies no clinically relevant differences in prevalences of small-for-gestational-age were observed between the three drugs. In addition, a secondary analysis using a cohort of pregnancies complicated by early-onset FGR demonstrated no significant differences in birth weight or adverse perinatal outcomes between treatment groups. While these results offer reassurance regarding labetalol's fetal safety profile, more detailed assessment of fetal growth trajectories is still needed to determine whether antihypertensive therapy influences fetal growth. This thesis also explored the potential of routinely collected electronic health record (EHR) data to generate robust real-world evidence for the management of HDP. An automated extraction algorithm was validated for identifying severe HDP, demonstrating high diagnostic accuracy and supporting the use of routinely collected EHR data as an alternative to manual chart review. Building on this work, a multicenter target trial emulation protocol was developed to investigate comparative treatment effectiveness and safety in over 10,000 pregnancies across six Dutch hospitals. By aligning treatment initiation with follow-up, this approach aims to minimize immortal time bias while addressing confounding by indication. In the postpartum setting, a systematic review and meta-analysis identified insufficient evidence to recommend a single preferred oral antihypertensive agent, although adjunctive furosemide was associated with lower systolic blood pressure postpartum day three. Overall, this thesis found no convincing evidence that methyldopa, labetalol, or nifedipine is consistently superior in the management of HDP. It highlights the limitations of existing comparative evidence and demonstrates the potential of routinely collected EHR data to support more rigorous observational research. Further large-scale, methodologically robust real-world studies are needed to clarify comparative effectiveness and safety and to inform more evidence-based, individualized treatment strategies for pregnancies complicated by HDP.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.